In our study, we found that the majority (97%) of pancreatic cancer cases possess the enzymatically active homozygous AA CYP2A6 allele compared to 75% and 89% of the healthy unrelated and related controls, respectively (Table S1). This evidence concerns the gene CYP2A6 and familial pancreatic carcinoma.